Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

NCT03167411 · Completed

Last updated 2026-05-28

This clinical trial tested how the diabetes medication bexagliflozin interacts with another diabetes injection called exenatide in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 20 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2017-05 · est. completion 2017-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03167411 ↗

Description as written by the study sponsor.

The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with one of the most commonly prescribed glucagon-like peptide 1 receptor agonist (GLP-1 RA) exenatide. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when administered with exenatide injection.

Treatments tested

Bexagliflozin Drug

Bexagliflozin tablets, 20 mg
Exenatide Injection also known as Byetta® Drug

Byetta® (Exenatide), 10 ug, bid, subcutaneous injection

Main thing measured	Cmax (Maximum Observed Plasma Concentration)
Sponsor	Theracos
Conditions studied	Type2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03167411 ↗